S-7
|
The philosophy of antiarrhythmic
therapy. Has it changed?
|
|
|
Günter Breithardt, Lars Eckardt,
Martin Borggrefe.
Department of Cardiology and Angiology, and Institute for Arteriosclerosis Research,
Westfälische Wilhelms-Universität of Münster, Münster, Germany
|
|
References
|
1.
|
Maisel AS, Scott N, Gilpin E, Ahnve S, Le Winter M,
Henning H, Collins D, Ross JJ:
Complex ventricular arrhythmias in patients with Q wave versus non-Q wave myocardial
infarction.
Circulation 1985; 72: 963-970.
|
2.
|
Rogers WJ, Epstein AE, Arciniegas JG, Crossley GHII,
Dailey SM, Kay GN, Little RE, MacLean WAH, Papapietro SE, Plumb VJ, Silber S, Baker AR,
Carlisle K, Cohen N, Cox M, Thomas C, Levson L, VonHagel D, Walton AE, et al:
Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction.
N Engl J Med 1992; 327: 227-233.
|
3.
|
Epstein AE, Hallstrom AP, Rogers WJ, Liebson PR, Seals
AA, Anderson JL, Cohen JD, Capone RJ, Wyse DG:
Mortality following ventricular arrhythmia suppression by encainide, flecainide, and
moricizine after myocardial infarction: the original design concept of the Cardiac
Arrhythmia Suppression Trial (CAST).
JAMA 1993; 270: 5451-5455.
|
4.
|
Akhtar M, Breithardt G, Camm AJ, Coumel P, Janse MJ,
Lazzara R, Myerburg RJ, Schwartz PJ, Waldo AL, Wellens HJ, Zipes DP:
CAST and beyond. Implications of the Cardiac Arrhythmia Suppression Trial. Task Force of
the Working Group on Arrhythmias of the European Society of Cardiology.
Circulation 1990; 81: 1123-1127.
|
5.
|
Rosen MR, Schwartz PJ:
The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on
their actions on arrhythmogenic mechanisms.
Circulation 1991; 84: 1831-1851.
|
6.
|
Waldo AL, Camm AJ, DeRuyter H, Friedman PL, MacNeil
DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP, Cagide A, Elizari MV, Gimeno G,
Aroney G, Aylward P, Calvert A, Campbell T, Davis M, Fletcher P, et al:
Effect of d-sotalol on mortality in patients with left ventricular dysfunction after
recent and remote myocardial infarction.
Lancet 1996; 348: 7-12.
|
7.
|
Doval HC, Nul DR, Grancelli HI, Perrone SV, Bortman
GR, Curiel R:
Randomised trial of low-dose amiodarone in severe congestive heart failure.
Lancet 1994; 344: 493-498.
|
8.
|
Garguichevich JJ, Ramos JL, Gambarte A, Gentile A,
Hauad S, Scapin O, Sirena J, Tibaldi M, Toplikar J:
Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction
and asymptomatic complex ventricular arrhythmias: Argentine pilot study of sudden death
and amiodarone (EPAMSA).
Am Heart J 1995; 130: 494-500.
|
9.
|
Burkart F, Pfisterer M, Kiowski W, Follath F,
Burckhardt D:
Effect of antiarrhythmic therapy on mortality in survivors of myo-cardial infarction with
asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct
Survival (BASIS).
J Am Coll Cardiol 1990; 16: 1711-1718.
|
10.
|
Wnuk Wojnar A, Giec L, Drzewiecki J, Trusz Gluza M,
Dabrowski A, Pasyk S:
Predictors of ventricular tachycardia inducibility in programmed electrical stimulation
and the effectiveness of serial drug testing: Polish multicenter study.
Pace 1990; 13: 2127-2132.
|
11.
|
Singh S, Fletcher RD, Fisher S, Deedwania P, Lewis D,
Massie B, Singh B, Colling CL:
Congestive heart failure: survival trial of antiarrhythmic therapy (CHF STAT).
Control Clin Trials 1992; 13: 339-350.
|
12.
|
Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A,
Schwartz PJ, Simon P:
Randomised trial of effect of amiodarone on mortality in patients with left-ventricular
dysfunction after recent myocardial infarction: EMIAT.
Lancet 1997; 349: 667-674.
|
13.
|
Cairns JA, Connolly SJ, Roberts R, Gent M:
Randomised trial of outcome after myocardial infarction in patients with frequent or
repetitive ventricular premature depolarisations: CAMIAT.
Lancet 1997; 349: 675-682.
|
14.
|
Jackman WM, Wang X, Friday KJ, Roman CA, Moulton KP,
Beckman KJ, McClelland JH, Twidale N, Hazlitt HA, Prior MI, Margolis PD, Calame JD,
Overholt ED, Lazzara R:
Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome)
by radiofrequency current.
N Engl J Med 1991; 324: 1605-1611.
|
15.
|
Jackman WM, Beckman KJ, McClelland JH, Wang X, Friday
KJ, Roman CA, Moulton KP, Twidale N, Hazlitt HA, Prior MI, Oren J, Overholt ED, Lazzara R:
Treatment of supraventricular tachycardia due to atrioventricular nodal reentry by
radiofrequency catheter ablation of slow-pathway conduction.
N Engl J Med 1992; 327: 313-318.
|
16.
|
Mirowski M, Mower MM, Reid PR:
The automatic implantable defibrillator.
Am Heart J 1980; 100: 1089-1092.
|
17.
|
The Antiarrhythmics Versus Implantable Defibrillators
(AVID) Investigators:
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients
resuscitated from near-fatal ventricular arrhythmias.
N Engl J Med 1997; 337: 1576-1583.
|
18.
|
Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL,
Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M:
Improved survival with an implanted defibrillator in patients with coronary disease at
high risk for ventricular arrhythmia.
N Engl J Med 1996; 335: 1933-1940.
|
19.
|
Bigger JT, for the Coronary Artery Bypass Graft (CABG)
Patch Trial Investigators:
Prophylactic use of implanted cardiac defibrillators in patients at high risk for
ventricular arrhythmias after coronary-artery bypass graft surgery.
N Engl J Med 1997; 337: 1569-1575.
|
